136 Tessa Jowell BRAIN MATRIX interim analysis: surgical and oncology outcomes in glioblastoma patients

Clicks: 15
ID: 326662
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #247 of 287 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 287 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction The Tessa Jowell BRAIN MATRIX (TJBM) is a programme of work aimed at improving the knowledge of and treatment for glioma, comprising a platform study with subsequent interventional clinical trials. Methods Interim analysis of first 500 patients from 11 specialist neurosurgical UK centres recruited to the TJBM study (14/Dec/2020-31/Jan/2025) with recruitment and data cleaning ongoing. Data snapshot 20/Feb/2026. Analysis conducted in R version 4.3.1. Results Amongst GBMs (n = 141), median age is 62 (IQR 55, 70), male 62.4%, ethnicity is White (94.3%), Asian (3.6%), Black (0.7%), other (1.4%). Patients presented mainly with headache (47%), cognitive (34%) or speech (36%) dysfunction and underwent surgery alone (26%), surgery and chemoradiotherapy (26%), surgery and radiotherapy (16%) or no intervention (14%). Gross total resection was achieved in 15% of cases, near total in 39% and subtotal resection in 27%. Median time from surgery to histological-molecular diagnosis was 27.5 (IQR 20, 42) days in England and 19.5 (IQR 13, 38) in Scotland. Median Intracranial Progression-Free Survival (IPFS) time was 10 months (95% CI: 8.4-13) from registration, with 44% (95% CI: 36-54%) of patients alive at 1 year and 15% (95% CI: 9-24%) at 2 years. Median Overall Survival (OS) time (date of diagnosis to date of death) was 14 months (95% CI: 12-15), with 57% (95% CI: 48-66%) of patients alive at 1 year and 21% (95% CI: 14-31%) at 2 years. IPFS and OS sub-group analyses were performed for age, gender, baseline performance, tumour type, and methylation status. Conclusion Despite neurosurgical and oncological advances, GBM patients still experience poor survival. Geographical and baseline factors need to be better explored to reduce barriers in healthcare access and ensure equitable representation in research.
Reference Key
openalex_W7204436739 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Vassili Crispi, Lucy Abell, Joshua Savage, Rhys Mant, Amanda Kirkham, Lucinda Billingham, Vinton Cheng, Victoria Wykes, Colin Watts
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag172.040
URL
https://academic.oup.com/neuro-oncology/article-pdf/28/Supplement_1/noag172.040/70805835/noag172.040.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.